Amryt Pharma
AMYT
AMYT was delisted on the 11th of April, 2023.
62 hedge funds and large institutions have $316M invested in Amryt Pharma in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 10 closing their positions.
472% more capital inflows, than outflows
Capital inflows: $18.6M | Capital outflows: $3.26M
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
3.13% more ownership
Funds ownership: 67.94% → 71.07% (+3.1%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
3% less funds holding
Funds holding: 64 → 62 (-2)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $6K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$9.8M |
| 2 |
Whitebox Advisors
Minneapolis,
Minnesota
|
+$3.48M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$1.47M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$988K |
| 5 |
Armistice Capital
New York
|
+$701K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$933K |
| 2 |
Stonepine Capital Management
Bend,
Oregon
|
-$527K |
| 3 |
Legal & General Group
London,
United Kingdom
|
-$376K |
| 4 |
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$306K |
| 5 |
Woodline Partners
San Francisco,
California
|
-$286K |
AMYT Hedge Fund Activity: Q3 2022 in Review
62 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in Amryt Pharma (AMYT) for Q3 2022, worth a combined $316M — up 0.62% from $314M a quarter earlier.
Fund positioning in AMYT was balanced in Q3 2022: 10 funds opened new positions, 10 closed out, 17 added to existing stakes and 7 trimmed.
The largest buyer was Man Group, opening a new position worth an estimated $9.8M. The largest seller was Nantahala Capital Management, cutting an estimated $933K.
- 62 institutional investors held Amryt Pharma (AMYT) as of Q3 2022, down from 64 in Q2 2022.
- Funds reported $316M of Amryt Pharma stock for Q3 2022, up 0.62% quarter-over-quarter.
- 10 funds opened new Amryt Pharma positions in Q3 2022 and 10 closed out, a net change of 0 holders.
- The largest Amryt Pharma buyer in Q3 2022 was Man Group, an estimated $9.8M added.
- The largest Amryt Pharma seller in Q3 2022 was Nantahala Capital Management, an estimated $933K sold.
Based on aggregated 13F filings for Q3 2022.